1. Structure-based optimization and biological evaluation of human 20α-hydroxysteroid dehydrogenase (AKR1C1) salicylic acid-based inhibitors
- Author
-
El-Kabbani, Ossama, Scammells, Peter J., Day, Tom, Dhagat, Urmi, Endo, Satoshi, Matsunaga, Toshiyuki, Soda, Midori, and Hara, Akira
- Subjects
- *
MATHEMATICAL optimization , *DEHYDROGENASES , *SALICYLIC acid , *ENZYME inhibitors , *ENZYME kinetics , *PROGESTERONE , *DRUG design , *CANCER cells - Abstract
Abstract: The tertiary structure of the Leu308Val mutant of human 20α-hydroxysteroid dehydrogenase (AKR1C1) in complex with the inhibitor 3,5-dichlorosalicylic acid (DCL) has been determined. Structures and kinetic properties of the wild-type and mutant enzymes indicate that Leu308 is a selectivity determinant for inhibitor binding. The Leu308Val mutation resulted in 13-fold and 3-fold reductions in the inhibitory potencies of DCL and 3-bromo-5-phenylsalicylic acid (BPSA), respectively. The replacement of Leu308 with an alanine resulted in 473-fold and 27-fold reductions in the potencies for DCL and BPSA, respectively. In our attempts to optimize inhibitor potency and selectivity we synthesized 5-substituted 3-chlorosalicylic acid derivatives, of which the most potent compound, 3-chloro-5-phenylsalicylic acid (K i = 0.86 nM), was 24-fold more selective for AKR1C1 relative to the structurally similar 3α-hydroxysteroid dehydrogenase (AKR1C2). Furthermore, the compound inhibited the metabolism of progesterone in AKR1C1-overexpressed cells with an IC50 value equal to 100 nM. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF